{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:40:53Z","timestamp":1761514853373,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2014\/03989-6"],"award-info":[{"award-number":["2014\/03989-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40618-021-01735-w","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T04:33:07Z","timestamp":1641443587000},"page":"999-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells"],"prefix":"10.1007","volume":"45","author":[{"given":"H. A.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-9831","authenticated-orcid":false,"given":"A. C.","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. S.","family":"Pugliesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-437X","authenticated-orcid":false,"given":"R. M. P.","family":"da Silva J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-4623","authenticated-orcid":false,"given":"M.","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3601-9470","authenticated-orcid":false,"given":"C. S.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"1735_CR1","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BMK, Findling JW et al (2015) Treatment of cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100:2807\u20132831. https:\/\/doi.org\/10.1210\/jc.2015-1818","journal-title":"J Clin Endocrinol Metab"},{"key":"1735_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing\u2019s disease. Endocr Rev 36:385\u2013486. https:\/\/doi.org\/10.1210\/er.2013-1048","journal-title":"Endocr Rev"},{"key":"1735_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101381","volume":"34","author":"A Ferriere","year":"2020","unstructured":"Ferriere A, Tabarin A (2020) Cushing\u2019s syndrome: treatment and new therapeutic approaches. Best Pract Res Clin Endocrinol Metab 34:101381. https:\/\/doi.org\/10.1016\/j.beem.2020.101381","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1735_CR4","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fendo.2020.00648","volume":"11","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Ferrigno R, De Martino MC et al (2020) Medical treatment of Cushing\u2019s disease: an overview of the current and recent clinical trials. Front Endocrinol 11:648. https:\/\/doi.org\/10.3389\/fendo.2020.00648","journal-title":"Front Endocrinol"},{"key":"1735_CR5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J et al (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8:748\u2013761. https:\/\/doi.org\/10.1016\/S2213-8587(20)30240-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1735_CR6","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1530\/JOE-18-0446","volume":"240","author":"S Pepe","year":"2019","unstructured":"Pepe S, Korbonits M, Iacovazzo D (2019) Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects. J Endocrinol 240:R21\u2013R45. https:\/\/doi.org\/10.1530\/JOE-18-0446","journal-title":"J Endocrinol"},{"key":"1735_CR7","doi-asserted-by":"publisher","first-page":"M73","DOI":"10.1530\/EJE-15-0320","volume":"173","author":"M Theodoropoulou","year":"2015","unstructured":"Theodoropoulou M, Reincke M, Fassnacht M, Komada M (2015) Decoding the genetic basis of Cushing\u2019s disease: USP8 in the spotlight. Eur J Endocrinol 173:M73-83. https:\/\/doi.org\/10.1530\/EJE-15-0320","journal-title":"Eur J Endocrinol"},{"key":"1735_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke M, Sbiera S, Hayakawa A et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47:31\u201338. https:\/\/doi.org\/10.1038\/ng.3166","journal-title":"Nat Genet"},{"key":"1735_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/cr.2015.20","volume":"25","author":"ZY Ma","year":"2015","unstructured":"Ma ZY, Song ZJ, Chen JH et al (2015) Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease. Cell Res 25:306\u2013317. https:\/\/doi.org\/10.1038\/cr.2015.20","journal-title":"Cell Res"},{"key":"1735_CR10","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.4103\/0366-6999.189047","volume":"129","author":"FF Jian","year":"2016","unstructured":"Jian FF, Li YF, Chen YF et al (2016) Inhibition of ubiquitin-specific peptidase 8 suppresses adrenocorticotropic hormone production and tumorous corticotroph cell growth in AtT20 cells. Chin Med J (Engl) 129:2102\u20132108. https:\/\/doi.org\/10.4103\/0366-6999.189047","journal-title":"Chin Med J (Engl)"},{"key":"1735_CR11","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1172\/JCI60417","volume":"121","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka H, Cooper O, Ben-Shlomo A et al (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121:4712\u20134721. https:\/\/doi.org\/10.1172\/JCI60417","journal-title":"J Clin Invest"},{"key":"1735_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/MED.0000000000000344","volume":"34","author":"A Ben-Shlomo","year":"2017","unstructured":"Ben-Shlomo A, Cooper O (2017) The role of tyrosine kinase inhibitors in the treatment of pituitary tumors: from bench to bedside. Curr Opin Endocrinol Diabetes Obes 34:301\u2013305. https:\/\/doi.org\/10.1097\/MED.0000000000000344","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1735_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1055\/a-1089-7806","volume":"52","author":"CS Martins","year":"2020","unstructured":"Martins CS, Camargo RC, Coeli-Lacchini FB et al (2020) USP8 mutations and cell cycle regulation in corticotroph adenomas. Horm Metab Res 52:117\u2013123. https:\/\/doi.org\/10.1055\/a-1089-7806","journal-title":"Horm Metab Res"},{"key":"1735_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1055\/s-0042-118613","volume":"48","author":"CS Martins","year":"2016","unstructured":"Martins CS, Camargo RC, Saggioro FP et al (2016) P27\/CDKN1B translational regulators in pituitary tumorigenesis. Horm Metab Res 48:840\u2013846. https:\/\/doi.org\/10.1055\/s-0042-118613","journal-title":"Horm Metab Res"},{"key":"1735_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1080\/15384101.2017.1403682","volume":"17","author":"M Fedele","year":"2018","unstructured":"Fedele M, Paciello O, De Biase D et al (2018) HMGA2 cooperates with either p27 kip1 deficiency or Cdk4 R24C mutation in pituitary tumorigenesis. Cell Cycle 17:580\u2013588. https:\/\/doi.org\/10.1080\/15384101.2017.1403682","journal-title":"Cell Cycle"},{"key":"1735_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4196\/kjpp.2019.23.3.171","volume":"23","author":"Z He","year":"2019","unstructured":"He Z, Chen L, Wang Q et al (2019) MicroRNA-186 targets SKP2 to induce p27 Kip1 -mediated pituitary tumor cell cycle deregulation and modulate cell proliferation. Korean J Physiol Pharmacol 23:171\u2013179. https:\/\/doi.org\/10.4196\/kjpp.2019.23.3.171","journal-title":"Korean J Physiol Pharmacol"},{"key":"1735_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","volume":"18","author":"J Yang","year":"2019","unstructured":"Yang J, Nie J, Ma X et al (2019) Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 18:26. https:\/\/doi.org\/10.1186\/s12943-019-0954-x","journal-title":"Mol Cancer"},{"key":"1735_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1677\/erc.1.00949","volume":"12","author":"M Musat","year":"2005","unstructured":"Musat M, Korbonits M, Kola B et al (2005) Enhanced protein kinase B\/Akt signalling in pituitary tumours. Endocrine Relat Cancer 12:423\u2013433. https:\/\/doi.org\/10.1677\/erc.1.00949","journal-title":"Endocrine Relat Cancer"},{"key":"1735_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1677\/ERC-08-0167","volume":"16","author":"Y Lin","year":"2009","unstructured":"Lin Y, Jiang X, Shen Y et al (2009) Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer 16:301\u2013310. https:\/\/doi.org\/10.1677\/ERC-08-0167","journal-title":"Endocr Relat Cancer"},{"key":"1735_CR20","doi-asserted-by":"publisher","first-page":"R331","DOI":"10.1530\/ERC-14-0188","volume":"21","author":"E Monsalves","year":"2014","unstructured":"Monsalves E, Juraschka K, Tateno T et al (2014) The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer 21:R331\u2013R344. https:\/\/doi.org\/10.1530\/ERC-14-0188","journal-title":"Endocr Relat Cancer"},{"key":"1735_CR21","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.3390\/cells8121584","volume":"8","author":"C Magaway","year":"2019","unstructured":"Magaway C, Kim E, Jacinto E (2019) Targeting mTOR and metabolism in cancer: lessons and innovations. Cells 8:1584. https:\/\/doi.org\/10.3390\/cells8121584","journal-title":"Cells"},{"key":"1735_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1535-7163.MCT-15-0891","volume":"15","author":"M Chanal","year":"2016","unstructured":"Chanal M, Chevallier P, Raverot V et al (2016) Differential effects of PI3K and dual PI3K\/mTOR inhibition in rat prolactin-secreting pituitary tumors. Mol Cancer Ther 15:1261\u20131270. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0891","journal-title":"Mol Cancer Ther"},{"key":"1735_CR23","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-11-1021","volume":"11","author":"SM Brachmann","year":"2012","unstructured":"Brachmann SM, Kleylein-Sohn J, Gaulis S et al (2012) Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther 11:1747\u20131757. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-1021","journal-title":"Mol Cancer Ther"},{"key":"1735_CR24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/ml200156t","volume":"2","author":"MT Burger","year":"2011","unstructured":"Burger MT, Pecchi S, Wagman A et al (2011) Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett 2:774\u2013779. https:\/\/doi.org\/10.1021\/ml200156t","journal-title":"ACS Med Chem Lett"},{"key":"1735_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12020-018-1677-2","volume":"62","author":"C Pivonello","year":"2018","unstructured":"Pivonello C, Patalano R, Solari D et al (2018) Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. Endocrine 62:663\u2013680. https:\/\/doi.org\/10.1007\/s12020-018-1677-2","journal-title":"Endocrine"},{"key":"1735_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","volume":"11","author":"S-M Maira","year":"2012","unstructured":"Maira S-M, Pecchi S, Huang A et al (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-Kinase inhibitor. Mol Cancer Ther 11:317\u2013328. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0474","journal-title":"Mol Cancer Ther"},{"key":"1735_CR27","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/0008-5472.CAN-09-2951","volume":"70","author":"V Cerovac","year":"2010","unstructured":"Cerovac V, Monteserin-Garcia J, Rubinfeld H et al (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 70:666\u2013674. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2951","journal-title":"Cancer Res"},{"key":"1735_CR28","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-05-1189","volume":"66","author":"M Theodoropoulou","year":"2006","unstructured":"Theodoropoulou M, Zhang J, Laupheimer S et al (2006) Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 66:1576\u20131582. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1189","journal-title":"Cancer Res"},{"key":"1735_CR29","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","volume":"23","author":"P Furet","year":"2013","unstructured":"Furet P, Guagnano V, Fairhurst RA et al (2013) Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett 23:3741\u20133748. https:\/\/doi.org\/10.1016\/j.bmcl.2013.05.007","journal-title":"Bioorg Med Chem Lett"},{"key":"1735_CR30","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1210\/en.2006-0325","volume":"147","author":"D Romano","year":"2006","unstructured":"Romano D, Pertuit M, Rasolonjanahary R et al (2006) Regulation of the RAP1\/RAF-1\/extracellularly regulated kinase-1\/2 cascade and prolactin release by the phosphoinositide 3-kinase\/AKT pathway in pituitary cells. Endocrinology 147:6036\u20136045. https:\/\/doi.org\/10.1210\/en.2006-0325","journal-title":"Endocrinology"},{"key":"1735_CR31","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1210\/en.2007-1696","volume":"149","author":"C Lu","year":"2008","unstructured":"Lu C, Willingham MC, Furuya F, Cheng S (2008) Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 149:3339\u20133345. https:\/\/doi.org\/10.1210\/en.2007-1696","journal-title":"Endocrinology"},{"key":"1735_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0029-1202832","volume":"118","author":"M Kowarik","year":"2009","unstructured":"Kowarik M, Onofri C, Colaco T et al (2009) Platelet-derived growth factor (PDGF) and PDGF receptor expression and function in folliculostellate pituitary cells. Exp Clin Endocrinol Diabetes 118:113\u2013120. https:\/\/doi.org\/10.1055\/s-0029-1202832","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1735_CR33","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.1016\/j.wneu.2019.07.032","volume":"130","author":"H Tang","year":"2019","unstructured":"Tang H, Zhu D, Zhang G et al (2019) AFAP1-AS1 promotes proliferation of pituitary adenoma cells through miR-103a-3p to activate PI3K\/AKT signaling pathway. World Neurosurg 130:e888\u2013e898. https:\/\/doi.org\/10.1016\/j.wneu.2019.07.032","journal-title":"World Neurosurg"},{"key":"1735_CR34","first-page":"1238","volume":"11","author":"H Tang","year":"2018","unstructured":"Tang H, Hou B, Ye Z et al (2018) Knockdown of long non-coding RNA AFAP1-AS1 inhibits growth and promotes apoptosis in pituitary adenomas. Int J Clin Exp Pathol 11:1238\u20131246","journal-title":"Int J Clin Exp Pathol"},{"doi-asserted-by":"publisher","unstructured":"Zheng Z, Zhang Y, Zhang Z, et al (2017) Effect of miR-106b on invasiveness of pituitary adenoma via PTEN-PI3K\/AKT. Med Sci Monit 23:1277\u20131285. https:\/\/doi.org\/10.12659\/MSM.900092","key":"1735_CR35","DOI":"10.12659\/MSM.900092"},{"key":"1735_CR36","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1210\/en.2012-1908","volume":"154","author":"C Dai","year":"2013","unstructured":"Dai C, Zhang B, Liu X et al (2013) Inhibition of PI3K\/AKT\/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 154:1247\u20131259. https:\/\/doi.org\/10.1210\/en.2012-1908","journal-title":"Endocrinology"},{"key":"1735_CR37","doi-asserted-by":"publisher","first-page":"52500","DOI":"10.1074\/jbc.M404571200","volume":"279","author":"A Rose","year":"2004","unstructured":"Rose A, Froment P, Perrot V et al (2004) The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary \u03b1T3 cells by protein kinase C\u03b1-mediated negative regulation of Akt. J Biol Chem 279:52500\u201352516. https:\/\/doi.org\/10.1074\/jbc.M404571200","journal-title":"J Biol Chem"},{"key":"1735_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2020.111090","volume":"520","author":"C Urbani","year":"2021","unstructured":"Urbani C, Mattiello A, Ferri G et al (2021) PCB153 reduces apoptosis in primary cultures of murine pituitary cells through the activation of NF-\u03baB mediated by PI3K\/Akt. Mol Cell Endocrinol 520:111090. https:\/\/doi.org\/10.1016\/j.mce.2020.111090","journal-title":"Mol Cell Endocrinol"},{"key":"1735_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1124\/jpet.114.212910","volume":"350","author":"EP Jane","year":"2014","unstructured":"Jane EP, Premkumar DR, Morales A et al (2014) Inhibition of phosphatidylinositol 3-kinase\/AKT signaling by NVP-BKM120 promotes ABT-737\u2013induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells. J Pharmacol Exp Ther 350:22\u201335. https:\/\/doi.org\/10.1124\/jpet.114.212910","journal-title":"J Pharmacol Exp Ther"},{"key":"1735_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/JME-14-0225","volume":"54","author":"M Labeur","year":"2015","unstructured":"Labeur M, W\u00f6lfel B, Stalla J, Stalla GK (2015) TMEFF2 is an endogenous inhibitor of the CRH signal transduction pathway. J Mol Endocrinol 54:51\u201363. https:\/\/doi.org\/10.1530\/JME-14-0225","journal-title":"J Mol Endocrinol"},{"doi-asserted-by":"publisher","unstructured":"Long R, Liu Z, Li J, Yu H (2019) COL6A6 interacted with P4HA3 to suppress the growth and metastasis of pituitary adenoma via blocking PI3K-Akt pathway. Aging 11:8845\u20138859. https:\/\/doi.org\/10.18632\/aging.102300","key":"1735_CR41","DOI":"10.18632\/aging.102300"},{"key":"1735_CR42","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1159\/000505923","volume":"110","author":"MC V\u00e1zquez-Borrego","year":"2020","unstructured":"V\u00e1zquez-Borrego MC, Fuentes-Fayos AC, Herrera-Mart\u00ednez AD et al (2020) Statins directly regulate pituitary cell function and exert antitumor effects in pituitary tumors. Neuroendocrinology 110:1028\u20131041. https:\/\/doi.org\/10.1159\/000505923","journal-title":"Neuroendocrinology"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01735-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01735-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01735-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T09:21:37Z","timestamp":1649582497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01735-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01735-w","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"21 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study followed the standards of the Brazilian College of Animal Experimentation (COBEA) and was approved by the Animal Ethics Committee of the Ribeirao Preto Medical School of University of Sao Paulo, Brazil (Protocols n\u25e6 180\/2011 and 186\/2011).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of study, which does not involve human subjects, consent is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}